Results 151 to 160 of about 461,523 (268)
A porous parylene‐coated electrode loaded with dexamethasone was developed to reduce inflammation after cochlear implantation. In guinea pigs, the device provided sustained drug release, maintained biocompatibility, improved auditory brainstem response thresholds, and reduced inflammatory cell infiltration and TNF‐α expression.
Chi‐Chieh Chang +11 more
wiley +1 more source
Special Issue "New Molecular Mechanisms and Advanced Therapies for Solid Tumors". [PDF]
De Falco V.
europepmc +1 more source
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave +8 more
wiley +1 more source
Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors. [PDF]
Pum K +5 more
europepmc +1 more source
A GSH‐responsive AIE nanoplatform (TSH NPs) with RGD‐mediated tumor targeting co‐delivers a photosensitizer (TPA) and HCPT for extrahepatic cholangiocarcinoma. The system synergistically enhances PDT and chemotherapy by suppressing HIF‐1α/VEGF‐driven hypoxic adaptation, effectively overcoming PDT resistance.
Yong Qu +19 more
wiley +1 more source
Extrachromosomal DNA in Solid Tumors-Landscape, Immune Effects, and Resistance to Targeted Therapy. [PDF]
Badran O, Attarya S.
europepmc +1 more source
Using pixel‐aware digital light processing, the authors created high‐resolution, dissolvable microneedles from a PEGDA/VP matrix. These microneedles encapsulate curcumin and 5‐fluorouracil and dissolve in the skin, co‐delivering drugs directly to tumours.
Rutuja N. Meshram, Dimitrios A. Lamprou
wiley +1 more source
Population Pharmacokinetics of Trastuzumab Rezetecan in Patients With HER2-Expressing or Mutated Advanced Solid Tumors. [PDF]
Gao X +6 more
europepmc +1 more source
Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans +7 more
wiley +1 more source
Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors. [PDF]
Mechahougui H +9 more
europepmc +1 more source

